
Invikafusp alfa elicited clinically meaningful antitumor activity in patients with advanced solid tumors resistant to anti–PD-1/PD-L1 agents.

Invikafusp alfa elicited clinically meaningful antitumor activity in patients with advanced solid tumors resistant to anti–PD-1/PD-L1 agents.

Frailty assessments, particularly the G8 tool, BMI, and albumin, may identify mHSPC patients at higher risk for severe adverse events with upfront docetaxel, a study suggests.

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with HER2-positive breast cancer.

The EMBARK analysis showed most men regained testosterone after stopping enzalutamide/leuprolide or placebo/leuprolide for prostate cancer with good PSA response, and recovery was common across age groups.

Updated findings from a phase 2 study investigating the IL-2–binding monoclonal antibody AU-007 show a manageable safety profile with strong antitumor evidence.

ENVISION trial 18-month data show UGN-102 yielded a high initial complete response (79.6%) in recurrent low-grade intermediate-risk NMIBC, with 80.6% maintaining response. The gel formulation with mitomycin offers a nonsurgical chemoablation with favorable tolerability.

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, including TKD and non-TKD mutations.

Phase 2b SunRISe-1 data showed TAR-200 monotherapy achieved an 82.4% complete response rate in BCG-unresponsive, high-risk NMIBC with CIS. The 12-month CR rate was 45.9%, with durable responses and manageable safety. An FDA application is under review.

TAR-200 showed durable disease-free survival in high-risk, BCG-unresponsive papillary NMIBC in SunRISe-1, with high 6/9-month DFS rates and a low cystectomy rate.

In an interview, Stacy Loeb, MD, discussed a study analyzing prostate cancer misinformation on social media.

A retrospective analysis showed higher response rate for cabozantinib/nivolumab vs. lenvatinib/pembrolizumab in advanced RCC, with no significant survival or safety differences.

A phase 2 study showed that giving maintenance regorafenib could delay disease progression in patients with non-adipocytic soft tissue sarcomas.

Jethro C.C. Kwong discusses a novel artificial intelligence-based model, PROGRxN-BCa.

Quoc-Dien Trinh, MD, MBA, discusses a sub-analysis of the phase 3 ARANOTE trial, focusing on Black patients with metastatic hormone-sensitive prostate cancer.

Reduced-dose radiotherapy in head & neck cancer shows similar efficacy to standard dose but with lower toxicity, per findings from the UPGRADE-RT trial.

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head and neck cancer per KEYNOTE-689, introducing a potential new standard of care.

Levee Medical has begun its pivotal ARID II trial, studying the Voro Scaffold for improved continence after prostatectomy.

Felix Guerrero-Ramos, MD, PhD, discusses findings from cohort 4 of the phase 2 SunRISe-1 trial of TAR-200 in patients with high-risk, BCG-unresponsive NMIBC with papillary-only disease.

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.


Combining the antibody-drug conjugate disitamab vedotin with BCG elicited a high complete response rate in patients with HER2-expressing, high-risk NMIBC.

Long-term data from QUILT-3.032 showed that NAI plus BCG shows sustained responses in BCG-unresponsive bladder cancer with 84% cystectomy avoidance at 36 months.

Antibody-drug conjugates continue to show benefits in breast cancer, plus the FDA has fast-tracked an innovative AI tool to help identify pancreatic tumors.

Cretostimogene showed high and durable responses in heavily pretreated BCG-unresponsive NMIBC with CIS in a phase 3 trial. Well-tolerated with minimal high-grade TRAEs.

Joseph Jacob, MD, discusses data from the phase 2b SunRISe-1 study, cohort 2, evaluating TAR-200 in BCG-unresponsive high-risk NMIBC with carcinoma in situ.

Colin P.N. Dinney, MD, discusses updated translational analyses from the BOND-003 and CORE-001 trials.

Enfortumab vedotin plus pembrolizumab followed by surgery showed high complete response rates in advanced urothelial cancer.

The first patient has been enrolled in a trial evaluating ClarityDX Prostate’s impact on early prostate cancer detection, biopsy reduction, and healthcare efficiency.

With the clearance of an investigational new drug application from the FDA, a phase 1/2a study will evaluate VS-7375 in KRAS G12D-mutant solid tumors.

Patients with metastatic colorectal cancer who received frontline immune checkpoint inhibitor therapy had positive OS rates and durable responses vs chemotherapy alone.